Cholesteryl ester transfer protein (CETP) plays a central role in high-density lipoprotein (HDL) metabolism. Single nucleotide polymorphisms (SNPs) and haplotypes in the CETP gene were determined in 98 patients with untreated dyslipidemias and analyzed for associations with plasma CETP and plasma lipids before and during statin treatment. Individual CETP SNPs and haplotypes were both significantly associated with CETP enzyme mass and activity. However, only certain CETP haplotypes, but not individual SNPs, significantly predicted the magnitude of change in HDL cholesterol (HDL-C) and triglycerides. After adjusting for covariates and multiple testing, the TTCAAA haplotype showed a gene-dose effect in predicting the HDL-C increase (P¼0.03), while the TTCAAAGGG and AAAGGG haplotypes predicted a decrease in triglycerides (P¼0.04 both). This is the first study to demonstrate that SNP haplotypes derived from allelic SNP combinations in the CETP gene were more informative than single SNPs in predicting the response to lipid-modifying therapy with statins. The Pharmacogenomics Journal ( 
INTRODUCTION
Cholesteryl ester transfer protein (CETP) mediates the transfer of neutral lipids between lipoproteins and plays a central role in high-density lipoprotein (HDL) metabolism. CETP transfers cholesteryl esters associated with HDL to triglyceride-rich lipoproteins, facilitating the clearance of cholesteryl esters from plasma. 1 Although the potential contribution of CETP to reverse cholesterol transport suggests an antiatherogenic mode of action, knowledge of the physiologic role of CETP in lipoprotein metabolism remains incomplete. The overall effect of CETP on atherogenesis may vary depending on both metabolic context and molecular variation in the CETP gene. 2 Investigations of associations between genetic variants in CETP and cardiovascular phenotypes are numerous, but often conflicting in their findings. The Taq1B polymorphism of the CETP gene has been associated with plasma levels of CETP and HDL cholesterol (HDL-C) and with the risk of coronary heart disease (CHD). 3, 4 The Taq1B polymorphism has also been shown to serve as a marker of lipoprotein response to dietary intervention. 5, 6 Other studies have demonstrated a link between the CETP I405V gene polymorphism and HDL-C, but not with response to diet. 7, 8 Several other single nucleotide polymorphisms (SNPs) in the CETP gene have been associated with interindividual variation in CETP plasma concentrations, HDL-C levels and risk of cardiovascular disease. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] CETP deficiency associated with elevated HDL-C may, paradoxically, increase the risk for CHD in certain genotype/phenotype constellations. 21 However, in a large sib-pair linkage analysis, no relationship between allelic variation at the CETP locus and plasma HDL-C levels was detected, despite an association between CETP gene variation and plasma CETP concentrations. 22 One explanation for these conflicting data may be that analyses based on associations between individual SNPs and clinical phenotypes do not reflect the subtle interactions of many individual SNPs within the CETP gene. Analyses that employ haplotypes, the ordered array of SNP combinations in individual alleles, may enable more consistent and relevant associations. 23, 24 In this study, we sought to determine and compare the contribution of individual SNPs and haplotypes in the CETP gene to plasma CETP levels and activity, to lipid levels and to the response to treatment with 3-hydroxy-3-methylglutaray coenzyme A (HMG-CoA) reductase inhibitors (statins) in patients with previously untreated dyslipidemias.
RESULTS

Demographics and Disease Characteristics at Baseline
The study population was predominantly male with a mean age of 63710 years and presented with a typical risk profile for ischemic heart disease: arterial hypertension (65%), cigarette smoking (63%), metabolic syndrome (60%) and diabetes mellitus (32%). The prevalence of angiographically documented coronary heart disease (CAD) was 74%, and of a history of myocardial infarction (MI) was 18%, while CAD had been ruled out by angiography in 26%. A family history of MI was present in one-third of the patients. Aspirin (64%), beta blockers (52%), ACE inhibitors (47%) and diuretics (30%) were the most common medications used for the secondary prevention of CAD or as antihypertensive agents (Table 1) .
Association between CETP Gene Variation and Baseline Values
Nine SNPs across the CETP gene were selected for this study ( Figure 1 ) and haplotypes were derived from those SNPs as shown in Methods (Tables 2 and 3 ). Haplotype 1 (see Table  2 ) was not significantly associated with the lipid response after statin treatment, neither were smaller subsets derived from haplotype 1; therefore, only results for haplotype 2 (and subsets) are presented below. Unless indicated otherwise, all P-values reported below for association analyses with genotypes were adjusted for both covariates and for multiple comparison by permutation testing (for further details, see Methods).
CETP activity, mass and CETP specific activity at baseline CETP mass and activity were significantly associated with SNPs 1 and 3-6. The data for CETP mass at baseline were highly concordant with the data for CETP activity at baseline (r¼0.7, P¼0.001), with the exception of SNPs7 and 8, which were only significantly associated with CETP mass, but not with CETP activity after correction for multiple testing (Table 4 ). In contrast, except for SNP7, CETP specific activity was not significantly different among SNPs (Table 4) . Similar, the full CETP haplotype SNPs1-9 (TTCAAAGGG) and the smaller haplotypes SNPs4-6 (AAA), SNPs4-9 (AAAGGG) and SNPs1-6 (TTCAAA) significantly and dose-dependently decreased CETP mass and activity (Table 4) . Baseline CETP activities in association with haplotypes SNPs1-6, SNPs4-9 and the full haplotype SNPs1-9 are also depicted graphically (Figure 2, top panel) .
Lipid levels at baseline
The overall mean baseline levels (7SD) for total cholesterol, low-density lipoprotein cholesterol (LDL-C), HDL-C and The final prescribed doses were pravastatin 20 mg (n¼29) and 40 mg (n¼20), cerivastatin 0.2 mg (n¼1), 0.3 mg (n¼11) and 0.6 mg (n¼17), atorvastatin 20 mg (n¼18), 40 mg (n¼1), and 60 mg (n¼1), which corresponded to average doses of 28710 mg (median 20), 0.570.2 mg (median 0.6), and 23710 mg (median 20) for the pravastatin, cerivastatin, and atorvastatin group, respectively. E2 E3  E4 E5  E6 E7 E8  E9  E10 E11 E12  E13  E14  E15  E16 3'-UTR   SNP #  1 2  3 4  5  6  7  8  9   E1  E2 E3  E4 E5  E6 E7 E8  E9  E10 E11 E12  E13  E14  E15  E16 3'-UTR   SNP #  1 2  3 4  5  6  7  8  9 CETP Polymorphic Sites 
Based on a total of 120 haplotypes in the nondiseased population sample (82 unrelated Caucasians) and 196 haplotypes in the patients analyzed (98 unrelated Caucasians) groups. Smaller haplotypes-derived as a subset from haplotype 2-are components of haplotypes 2 and 9 (SNPs1-6: TTCAAA, in bold) or components of haplotypes 2, 8 and 13 (SNPs4-9: AAAGGG, within the box), or components of haplotypes 2, 5, 8, 9 and 13 (SNPs4-6: AAA, not highlighted). LDL-C/HDL-C ratio were 236738, 150741, 43712 and 3.771.6 mg/dl, respectively, and the median (25-75% quartile) of triglycerides was 171 (125-231) mg/dl (Table 1) . Except for a marginal association of baseline HDL-C with SNP7, and of baseline TG with haplotype SNPs4-9, when the P-value was adjusted for covariates alone (P¼0.04 and P¼0.05, respectively), and which lost their significance after correction for multiple comparison, baseline lipid values did not differ significantly in relation to any individual SNP or haplotype of CETP (Table 5) .
Association between CETP Gene Variation and Response to Statins CETP activity, CETP mass and CETP Specific activity
Significant reductions in CETP mass and CETP activity were noted after statin treatment. The overall mean percent reduction in CETP activity and CETP mass was 10.7 and 12.4%, respectively (data not shown). These changes were not significantly different between individual SNPs or haplotypes (data not shown).
LDL cholesterol
The overall mean percent reduction in LDL-C was 30.4%, and the mean percent reduction in LDL-C differed by individual statin group (24.0% for pravastatin, 38.2% for atorvastatin and 35.8% for cerivastatin; Po0.0001). No individual SNP was related to percent change in LDL-C (Table 5) . Furthermore, LDL-C response to statin treatment was unrelated to any of the haplotypes, except for an association of the haplotypes SNPs4-6(AAA) and SNPs4-9 (AAAGGG), with LDL-C response before adjustment for multiple comparison (P¼0.03 and 0.02, respectivley) ( Table 5) .
LDL-C/HDL-C ratio
No CETP SNP or haplotype was significantly associated with the change in LDL-C/HDL-C ratio (Table 5) .
HDL-C
The overall mean percent rise in HDL-C was 6.4%, and the mean increase in HDL-C by individual statin did not differ significantly. There was no interaction between baseline HDL-C and percentage of increase in on-treatment HDL-C. While no individual SNP was associated with percent change in HDL-C, a significant association with the haplotype SNPs1-6 (TTCAAA) and HDL-C response remained after adjustment for covariates and multiple testing (P¼0.03) ( Table 5) . Patients with two copies of this P-values are for the SNP/haplotype term from a regression model for baseline CETP activity, CETP mass or CETP specific activity with covariates of age, gender, BMI and the SNP/haplotype coded as an additive (0, 1, 2) term. In addition to the adjustment for covariates alone (P-value to the left), P-values r0.1 were adjusted for multiple comparisons by permutation testing (P-value to the right). P-values that achieved statistical significance of less than or equal to 0.05 are indicated by bold type. All Pvalues r0.1 are reported numerically.
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haplotype showed a mean increase in HDL-C of 23%, compared to only 6 and 3% increase in HDL-C for those with one or zero copies, respectively ( Figure 2 , middle panel). The haplotype TTCAAA in SNPs1-6 is a component of the full haplotype SNPs1-9 (TTCAAAGGG), yet the strength of the association decreased, when SNPs7-9 were included in the analysis (P¼0.06 for the full haplotype SNPs1-9). However, the difference in these two adjusted Pvalues may not be meaningful (Figure 2 middle panel) . Furthermore, the smaller haplotypes SNPs4-6 and SNPs4-9 were also marginally associated with the change in HDL-C before adjustment for multiple comparison (Table 5) . When a term for baseline CETP activity was added to the model associating percent change in HDL-C with the CETP haplotype SNPs1-6, the significance of the CETP haplotype term remained. Hence, the observed association between HDL-C response and CETP haplotype is independent of the relationship between CETP activity at baseline and CETP haplotype. In the regression model that included age, sex and body mass index (BMI) as covariates, the SNPs1-6 (TTCAAA) haplotype explained 7.5% of the variation in HDL response to statin treatment, compared to 5.9% of the variation explained by BMI and o1% by age and sex.
Triglycerides
The overall median percent reduction in triglycerides was 24.5%, and no significant differences were noted by individual statin. Except for a marginal association of SNP4 and SNP5, when P-values were adjusted for covariates alone (P¼0.03 and 0.05, respectively), no individual CETP SNP was significantly related to the change in triglyceride levels after adjustment for multiple comparison ( Table 5 ). The haplotype SNPs1-9 (TTCAAAGGG) remained significantly associated with percent change in triglycerides after adjustment for multiple testing (P¼0.04). Patients with two copies of this haplotype showed a median decrease in triglycerides of 32%, compared to a median decrease of 18 and 12% for those with one and zero copies, respectively ( Figure 2, bottom panel) . Additionally, the haplotype SNPs4-9 (AAAGGG) significantly predicted percent change in triglycerides (P¼0.04). The median decrease in triglycerides was 32, 20 and 8% for patients with two, one and zero copies of this haplotype (Figure 2 bottom panel) . Haplotype SNPs4-6 (AAA) was also associated with TG response after adjustment for covariates alone (P¼0.042), but lost its significance once adjusted for multiple comparison (Table 5 ).
In a model with age, sex and BMI as covariates, the full haplotype SNPs1-9 (TTCAAAGGG) explained 4.4% of the variance in triglycerides, as compared to 5.2% of the variance explained by BMI and o1% by age and sex.
DISCUSSION
Following statin therapy, the overall decrease in mean LDL-C in our study and in median triglyceride levels was 30 and 25%, respectively, and the average increase in HDL-C was 6.4%. Such ranges were to be expected for the agents and doses administered. 25, 26 After adjusting for covariates and multiple testing, significant associations were maintained between the increase in plasma HDL-C and the haplotype Please note that change in on-treatment lipid levels is reported as absolute change (in mg/dl). The estimate of relative change (percent change) based on these average values will not be accurate in case of very small changes; see Figure 2 for the precise average percent change in HDL-C and TG for selected haplotypes (where means were calculated from individual percent change). P-values are for the SNP/haplotype term from a regression model for lipid parameters with covariates of age, gender and BMI. In addition to the adjustment for covariates alone (P-value to the left), P-values r0.1 were adjusted for multiple comparisons by permutation testing (P-value to the right). Associations that achieved statistical significance of less than or equal to 0.05 are indicated by bold type. P-values after adjustment for covariates alone (P-values to the left) are from the SNP/haplotype term from a regression model for percent change from baseline in: (1) HDL-C and LDL-C/HDL-C ratio with covariates of age, gender, BMI and the SNP/haplotype coded as an additive term (0, 1, 2) for all SNPs and the haplotypes SNPs4-6 and 1-9; P-values for the haplotypes SNPs1-6 and 4-9 are from a recessive ((0, 1) vs (2) copies) model. (2) LDL-C with covariates of age, gender, statin, baseline triglycerides and the SNP/haplotype coded as additive term (0, 1, 2) for all SNPs and the haplotype SNPs1-6, 4-6 and 1-9; P-value for the haplotype SNPs4-9 is from a dominant (0 vs (1, 2) copies) model. (3) Log-transformed total triglycerides with covariates of age, gender, BMI, baseline triglycerides and all SNPs and haplotypes coded as an additive term (0, 1, 2).
Although the most significant P-value for the haplotype was reported after testing of models with the term coded as additive, recessive or dominant, the general minor differences in P-values between models may only be of statistical relevance due to the small sample size.
comprising SNPs1-6 (TTCAAA), and between the decrease in plasma triglyceride and the full CETP haplotype comprising nine SNPs (TTCAAAGGG), as well as the smaller haplotype built from SNPs4-9 (AAAGGG). In both instances, the most favorable lipid-modifying response to statins was observed in individuals homozygous for the respective CETP haplotype. These new findings of an inherited, and thus predictable, variability in individual HDL/triglyceride response to statin therapy relate well to the pathophysiologic function of CETP of primarily modifying HDL and VLDL but not LDL composition.
Although the decrease in LDL-C has been the focus for explaining the benefits of statin therapy for a long time, recent data support the important additional role of a change in HDL-C and triglycerides during statin treatment. 27 A recent angiographic study has indicated that antioxidant supplementation to lipid-lowering therapy prevented HDL-C elevation and was associated with a worse coronary angiographic outcome; 28, 29 conversely, a predominant increase of HDL-C by gemfibrozil without a major reduction in LDL-C levels was associated with a significant reduction in the rate of coronary events. 30 Finally, patients with low HDL-C benefitted most when treated with fluvastatin in the Lipoprotein and Coronary Atherosclerosis Study (LCAS). 31 No association was seen between changes in plasma lipids during statin therapy and individual SNPs, supporting our findings that the interaction of multiple CETP SNPs within a haplotype is a more powerful determinant of the clinical phenotype than are individual SNPs. This has also been demonstrated for the b2-adrenergic receptor and the response to a b2-bronchodilator. 23 Haplotype determination may be of general utility in the identification of diseaseassociated alleles. 32 In a large family study on the impact of genetic variants and the effect of SNPs and haplotypes on baseline lipid levels, a similar observation was made for several genes involved in lipid metabolism, including the CETP gene, where haplotypes derived from SNP combinations resulted in stronger significance of the genotypephenotype association than did individual SNPs. 24 CETP protein mass and activity are intermediate phenoypes much closer to the CETP genotype than any other biochemical phenotype (i.e. lipid concentrations). Accordingly, others have reported recently that certain novel CETP gene promoter SNPs (À629 A/C and À971 G/A) were associated with baseline CETP levels, but not with baseline HDL. 33 The latter study also reported that haplotype analyses of 10 novel and three previously reported polymorphisms in the CETP gene promoter were more informative than SNPs considered separately in the association analysis. 33 It is a crucial question as to why changes in HDL-C were significantly associated with CETP haplotypes, whereas changes in CETP mass and activity were not. An explanation for this finding may lie in the fact that those CETP haplotypes linked to the greatest increases in HDL-C already produced the lowest CETP expression at baseline. Hence, the slight 10-12% statin-induced lowering of CETP might have brought down CETP to a critical threshold at which the deficiency of CETP translates into discernible increases in HDL-C. Such a concept is consistent with studies of genetic CETP deficiency in which heterozygotes have only slightly increased HDL-C, but homozygotes have a massive HDL-C elevation. 34 Of note is SNP7, wherein the substitution of C for G at amino acid 373 produced an increase in mass, yet the specific activity decreased. Whether these findings are due to chance or indicate a functional effect on CETP gene expression needs to be evaluated by further studies.
We found no significant association of any individual SNP (or haplotype) of CETP with baseline levels of HDL-C, LDL-C or triglycerides after correction for multiple testing. Several previous studies have demonstrated such associations for HDL-C, specifically with SNP4 (TaqIB). [3] [4] [5] 8, [35] [36] [37] In some reports, the association was seen only in subgroups, such as ex-and nonsmokers, 38 or in women, but not in men. 39 Alhough we could not replicate the association of an increased baseline HDL-C in the presence of the mutant B2 allele of SNP4, the strong stepwise decrease in CETP mass and activity associated with the number of B2 alleles of SNP4 clearly underlines such an expected effect on HDL-C. With respect to SNP 7 (A373P) and SNP8 (R451Q), the Copenhagen City Heart Study found a decrease in HDL-C and ApoA1 in carriers of the mutant allele, both in men and women.
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Despite the low frequency of these mutant alleles, we also observed a significant decrease in HDL-C associated with the SNP7 (A373P) CETP polymorphism. Furthermore, consistent with the HDL effect reported by Agerholm et al, 11 significant associations with CETP mass and activities of the opposite type (increase in the presence of the mutated allele) were observed for both the SNP7 (A373P) and SNP8 (R451Q) polymorphisms in our study (Tables 4 and 5 ). In other studies, similar to our findings, a significant relationship between variation in the CETP gene and CETP plasma concentrations was observed, but no relationship with HDL-C levels, especially in normolipidemic subjects, was seen. 22, [40] [41] [42] Obviously, the association of the CETP protein product with the CETP genotype is closer than that with HDL-C. Thus, a lack of significance with HDL-C is to be expected in smaller samples. Furthermore, P-values are most often not corrected for multiple testing, and the sensitivity of individual analytic techniques, and known confounders influencing HDL-C (i.e. smoking status, level of exercise, alcohol consumption) may vary between studies.
Limitations
Three different statin agents were used and two different doses were applied for pravastatin (20 and 40 mg) and cerivastatin (0.3 and 0.6 mg) about evenly in the respective treatment groups, raising concerns about the impact of confounding by such variation in drug agent and dose on haplotype effects. However, it should be noted that a doubling of dose results-on average-in a decrease of 6% in LDL-C, while the individual response to a statin agent CETP Haplotypes predict modifying response to statins BR Winkelmann et al ranges from almost zero to 60% decrease, and for triglyceride response from up to 50% increase to 60% decrease. 43 Furthermore, the average decrease in LDL-C in our study was about similar for cerivastatin-and atorvastatin-treated patients, À36 and À38%, respectivley, and À24% LDL-C response to pravastatin in our study matched results of a Spanish outpatient study with 20% LDL lowering. 44 We deliberately did not choose to introduce a dose equivalence factor for our analysis, as others have chosen, 45 but tested for such an interaction. Since a significant interaction between LDL response and statin agent was confirmed in our study, this confounding effect was accounted for in the multivariate analysis of CETP haplotypes and LDL response. However, no significant interaction was observed for triglycerides or HDL.
Overall, genotype variation in the CETP gene, based on the haplotype SNPs1-6 (TTCAAA), explained 7.5% of the variance in HDL response to statins, which was more than the 5.9% of the variance explained by BMI. A multifactorial polygenic and environmental impact on lipid levels in humans is well known. For example, Talmud et al 46 reported that the genetic contribution of three key genes (including CETP) on the variance in baseline HDL in 2773 subjects of the second Northwick Park Heart study was only 2.5%, based on SNPs that were associated with differences in baseline levels in HDL.
Clinical relevance
In our study, genotyping for CETP haplotypes predicted the average response in HDL-C during statin therapy, such that there was on average almost no change in HDL-C if the corresponding CETP haplotype (TTCAAA) was absent ( þ 0.4 mg/dl or r3% mean increase), as compared to an average increase of þ 2 mg/dl or B6% in the presence of one copy of the haplotype, and about þ 8 mg/dl or B20% increase in HDL-C if the individual was homozygous for the haplotype. Although reduction of cardiovascular events has been attributed to pharmacologic increases in HDL-C, 30 the evidence is less well documented for HDL-C as compared to LDL-C, where a 1% lowering in LDL-C has been found to be associated with a 2% decrease in clinical events. From a meta-analysis of four prospective epidemiologic studies, an increase in 1 mg/dl HDL-C was equated with an independent reduction in the incidence of coronary events of 2% in men and 3% in women. 47 However, similar estimates of benefit have been derived from studies with cholestyramine (Lipid Research Clinics Prevention Trial) and gemfibrocil (Helsinki Heart Study), where a 1% increase in HDL-C was associated with 0.6 and 2-3% decrease in CHD events, respectively. 48 Furthermore, evidence from the large statinintervention studies (CARE, LIPID) showed that baseline HDL-C modulated the clinical event rate despite a similar lowering of LDL-C. 27 Taken together, the ability to predict an increase in HDL, or to identify HDL-C low responders during statin therapy will be of clinical relevance.
In conclusion, we found robust associations between both CETP SNPs and haplotypes and baseline levels of CETP activity and CETP mass, but not any more between SNPs and the lipid-response to treatment with statins. However, HDL-C and triglyceride response to lipid lowering therapy differed significantly based on the genetic background of the CETP gene according to haplotypes derived from a combination of informative SNPs. Considering the large degree of individual variation in clinical response to statins and other lipid-modifying therapies 49 and the current limitations in the ability to predict individual response, this study is the first to demonstrate that haplotype analysis may help to predict the response to lipid-modifying therapy with statins. Furthermore, it underlines the more informative character of haplotypes derived from SNP combinations as opposed to individual SNPs.
MATERIALS AND METHODS
Study Design
Patients in the clinical cohort who were not receiving any lipid-lowering therapy at baseline, who were prescribed pravastatin, atorvastatin or cerivastatin, and who had both baseline and follow-up lipid level measurements were considered for analysis (103 patients). Five of these patients with ambiguous genotypes inconsistent with any observed haplotype were excluded from the association analysis. All patients were participants in the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study (described in detail in Winkelmann et al 50 ) . The agent and dose of statin administered were targeted as clinically indicated to achieve an LDL-C reduction to 130 mg/dl for primary and 100 mg/dl for secondary prevention. Biochemical parameters were obtained prior to treatment (baseline) and measured again after a median of 5 weeks of treatment. The percent change in the levels of LDL-C, HDL-C and triglycerides were considered the primary measures of clinical response. Patients selected for the present study had a physical examination, including anthropometric measurements of weight, height and waist and hip circumferences. The diagnoses of CAD, MI, dyslipidemia, hypertension, metabolic syndrome and diabetes mellitus were established or ruled out using a standardized methodology, which included coronary angiography and an extensive laboratory evaluation (see Appendix III in Winkelmann et al 50 ) . In brief, a positive family history for MI was defined as a history of first MI at age r55 years for males, r60 years for females in at least one first-degree relative; hypertension was defined by either a documented history of hypertension, treatment with antihypertensives or a blood pressure Z140 and/or Z90 mmHg; diabetes mellitus was defined according to American Diabetes Association (ADA) criteria, and metabolic syndrome was defined by fasting insulin Z15 IU/l or fasting plasma glucose Z110 mg/dl or a pathologic oral glucose tolerance test (impaired or diabetic oral glucose tolerance test) and the presence of two out of four components (abdominal obesity, hypertension, dyslipidemia, hyperuricemia).
The inclusion criteria for LURIC stipulated that subjects be Caucasian of German ancestry, in a stable clinical condition CETP Haplotypes predict modifying response to statins BR Winkelmann et al without any acute illness other than acute coronary syndromes, or any predominant chronic noncardiac disease. 50 The LURIC study protocol and the lipid-lowering intervention substudy described here were approved by the Institutional Review Board of the Ethics Committee of the Landesärztekammer Rheinland Pfalz, Mainz, Germany (No. 1997-203) . The study was performed in adherence to the principles of the Declaration of Helsinki.
Lipid and Lipoprotein Analysis
Plasma lipids and lipoproteins were measured centrally by standard techniques in the core laboratory (Freiburg University, Germany). A combined ultracentrifugation and precipitation assay was used for lipoprotein separation, which essentially followed the protocol of the Lipid Research Clinics Program, 51 with modifications previously described. 52 The day-to-day coefficients of variation for total cholesterol, LDL-C, HDL-C and triglycerides were 1.1, 2.2, 2.1, and 1.7%, respectively. CETP Activity, CETP Mass and CETP Specific activity CETP activity was determined in the laboratory of A Tall, New York, NY, USA using a commercial kit according to the manufacturer's instructions (Roar Biomedical, Inc., New York, NY, USA). The fluorescent assay kit includes synthetic donor and acceptor particles. The fluorescent neutral lipid is present in a self-quenched state when contained within the core of the donor. CETP-mediated transfer is determined by the increase in fluorescence intensity as the fluorescent neutral lipid is removed from the self-quenched donor to the acceptor. CETP mass was determined in the laboratory of W März, Freiburg, Germany using a commercial kit according to the manufacturer's instructions (Wako Pure Chemicals Industries, Ltd, Osaka, Japan). The assay is a sandwich enzyme immunoassay. CETP specific activity was determined by dividing values for CETP activity by values for CETP mass.
Determination of Genetic Variation
SNP and haplotype analysis DNA sequence was obtained from a population sample consisting of 82 unrelated human individuals of broad population diversity, including Caucausian, Asian, AfricanAmerican and Hispanic subjects. This population provides a representative sampling of human genetic variation and serves as a comparative baseline for genotypic analysis of the study population. 23, 53 CETP SNPs in these individual samples were discovered and the unphased genotypes were determined by sequencing the polymerase chain reaction (PCR) products of the genomic DNA. A total of 66 SNPs were discovered for the CETP gene, but only a subset of nine (SNPs1-9) was selected to represent coverage across the entire gene (Figure 1) . Five of the nine SNPs reported here have not been previously described (SNPs 1-3, 5 and 6). The subset of SNPs was selected using the following procedure. We discarded all SNPs that had a minor allele frequency o1% in the Caucasian cohort of our discovery population. Haplotypes were then inferred for all of the remaining SNPs using an extension of Clark's algorithm. 54 Next, an information theory algorithm was used to select the smallest subset of SNPs that still represented 95% of the genetic diversity at the locus. 55 This procedure eliminates SNPs that provide redundant information because of linkage disequilibrium and SNPs that define very low-frequency haplotypes. This procedure resulted in a subset of nine SNPs (SNPs1-9) that were used to represent coverage across the entire gene. The clinical cohort was then genotyped for this set of nine SNPs and haplotypes were inferred in that cohort.
CETP haplotypes were constructed using all nine selected SNPs (SNPs1-9) ( Table 2 ). The two most common haplotypes (haplotypes 1 and 2) were selected for further analysis. Smaller haplotypes not covering the entire gene were derived from haplotype 1 (data not shown) and haplotype 2 using fewer than the full nine SNPs (Table 3 ). It should be noted that association analyses using either the SNPs1-9 full haplotype or the smaller haplotypes are carried out using nonidentical, but overlapping, patient groupings. For example, the haplotype constructed using SNPs4-9 from haplotype 2 (AAAGGG) is also a component of haplotypes 8 and 13 ( Table 2) .
Genotyping of clinical samples
The genotype for each of the polymorphic sites in CETP was determined for each patient using the MassARRAYt System (Sequenom, Inc., San Diego, CA, USA). In brief, each genotyping assay involved PCR amplification from genomic DNA in a target region defined by specific primers for the respective CETP polymorphic sites, purification of the amplification product, annealing of the indicated extension primer to one strand of the amplification product adjacent to the polymorphic site, extending the primer by one nucleotide using the MassEXTENDt reaction (Sequenom, Inc.) and detection of the allele-specific extension product by mass spectrometry.
Statistical Analysis
The individual SNPs and the two most common haplotypes (1 and 2), and subsets of those (see Tables 2 and 3) were examined for associations with baseline levels and on-statin treatment percent changes in CETP (activity, mass, specific activity), and in plasma lipids (HDL-C, LDL-C, log-transformed triglycerides) by linear regression using a continuous term for the specific SNP or haplotype (additive model coded as 0, 1 and 2), as predictors. Zero was used as coding if the SNP or haplotype was not present in the CETP gene of this individual, 1 was the coding for a heterozygous state (presence of the SNP or haplotype in one allele of the CETP gene), and 2 the coding for homozygosity (presence of the SNP or haplotype in both alleles). In cases of significance (Po0.05), the dominant (0 codes for the presence of none or one allele with the respective SNP or haplotype, and 1 for homozygosity) and recessive (0 codes for the absence, and 1 for the presence of at least one allele of the respective SNP or haplotype) models were considered and the most significant associations reported. Covariates included age, gender, BMI for CETP, HDL-C, LDL-C/HDL-C ratio, plus log-transformed baseline plasma levels for TG, and age, gender, logtransformed baseline TG and statin agent for LDL-C. For adjustment, covariates were selected based on whether a significant association was found by univariate testing of the respective end point. When terms for alcohol use and smoking were incorporated into the models for HDL-C, they did not significantly improve the fit of the model, nor did they have a major impact on the significance of the genetic term in the model. Neither did the omission of the baseline triglyceride term as a covariate in the models for change in LDL-C and triglycerides or adding it into the other models improve the fit.
To adjust for multiple testing, permutation tests were constructed to test the null hypothesis of no association across the nine SNPs or the two most common haplotypes and subsets derived from those haplotypes. The observed Pvalues were compared to empirical distributions of minimum P-values, based on 800-2400 permuted samples. Pvalues adjusted both for covariates and multiple testing were used. All analyses were conducted using SAS s (Statistical Analysis Software, version 8.1, SAS Institute, Inc., Cary, NC, USA) and S-Plus s 2000 Release 3 (MathSoft Inc., Seattle, WA, USA).
